Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

Table 4 Local infection as an adverse event vs. baseline

		Occurrence of local infection as adverse event		Total
		Yes	No	Total
Local infection as baseline	Yes	52	1270	1322
Local infection as baseline	No	15	358	373
Total		67	1628	1695

Information on baseline infection was missing in one subject with local infection as adverse event and in 90 subjects without it. The OR was 0.98; 95% CI: 0.54–1.76.